Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

TPEX/8432 stock hub

TPEX/8432 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TPEX/8432is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

Taipei Exchange

Market data

Live price

Current market quote for this ticker.

Current price

TPEX/8432

In the news

Latest news · TPEX/8432

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12P50 15.5P75 22.5

Trailing P/E13.4

P25 14.4P50 18P75 31.9

ROE11.4

P25 -16.2P50 0.3P75 9.8

ROIC18.2

P25 -11.7P50 -0.2P75 8.8

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TPEX/8432 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

239

Groups with data

Currency

TWD

Showing 239 of 239 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Taiwan
Country code	TW
Employees	76
Employees Change	-4%
Employees Change Percent	-5
Enterprise value	TWD 1.7B
Exchange	Taipei Exchange
Financial currency	TWD
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	TW0008432006
Last refreshed	2026-05-10
Market cap	TWD 2B
Price	TWD 51.3
Price currency	TWD
Rev Per Employee	17,568,710.53x
Sector	Healthcare
Sic	2834
Symbol	tpex/8432
Website	https://www.tshbiopharm.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	7.49%
EV Earnings	11.41x
EV/EBIT	7.37x
EV/EBITDA	6.96x
EV/FCF	6.09x
EV/Sales	1.26x
FCF yield	14.03%
P/B ratio	1.12x
P/E ratio	13.4x
P/S ratio	1.48x
PE Ratio10 Y	32.56x
PE Ratio3 Y	22.53x
PE Ratio5 Y	25.69x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	17.11%
EBITDA Margin	18.12%
FCF margin	20.7%
Gross margin	51.45%
Gross Profit	TWD 686.9M
Gross Profit Growth	12.84%
Gross Profit Growth Q	4.12%
Gross Profit Growth3 Y	19.82%
Gross Profit Growth5 Y	21.36%
Net Income	TWD 147.6M
Net Income Growth	43.86%
Net Income Growth Q	27.3%
Net Income Growth Quarters	3%
Net Income Growth Years	4%
Net Income Growth3 Y	40.55%
Net Income Growth5 Y	25.41%
Pretax Margin	18.34%
Profit Margin	11.05%
Profit Per Employee	TWD 1.9M
Profitable Years	7
ROA	7.4
Roa5y	4.52
ROCE	12.98
ROE	11.44
Roe5y	7.16
ROIC	18.19
Roic5y	15.85

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-2.1%
Cagr1y	9.49%
Cagr3y	6.93%
Cagr5y	6.89%
Div CAGR10	0.09%
Div CAGR3	9.83%
Div CAGR5	3.33%
EPS Growth	43.4
EPS Growth Q	26.58
EPS Growth Quarters	3
EPS Growth Years	2
EPS Growth3 Y	40.51
EPS Growth5 Y	25.5
FCF Growth	79.29%
FCF Growth Q	553.11%
FCF Growth3 Y	114.93%
FCF Growth5 Y	37.14%
OCF Growth	77.94%
OCF Growth Q	520.68%
OCF Growth10 Y	17.48%
OCF Growth3 Y	100.26%
OCF Growth5 Y	36.64%
Revenue Growth	11.05x
Revenue Growth Q	-0.45x
Revenue Growth Quarters	4x
Revenue Growth Years	4x
Revenue Growth3 Y	20.38x
Revenue Growth5 Y	26.17x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	TWD 0.69
Assets	TWD 2B
Cash	TWD 582.3M
Current Assets	TWD 1.4B
Current Liabilities	TWD 223.3M
Debt	TWD 17.1M
Debt EBITDA	TWD 0.07
Debt Equity	TWD 0.01
Debt FCF	TWD 0.06
Equity	TWD 1.8B
Interest Coverage	277.9
Liabilities	TWD 229.4M
Long Term Assets	TWD 543.8M
Long Term Liabilities	TWD 6.1M
Net Cash	TWD 565.1M
Net Cash By Market Cap	TWD 28.69
Net Cash Growth	-35.37%
Net Debt EBITDA	TWD -2.34
Net Debt Equity	TWD -0.32
Net Debt FCF	TWD -2.05
Tangible Book Value	TWD 1.2B
Tangible Book Value Per Share	TWD 30.54
WACC	6.02

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.44
Inventory Turnover	4.03
Net Working Capital	TWD 644.7M
Quick ratio	3.56
Working Capital	TWD 1.2B
Working Capital Turnover	TWD 1.15

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.22%
Dividend Growth	65.63%
Dividend Growth Years	1%
Dividend per share	TWD 2.61
Dividend Years	15
Dividend Yield	5.09%
Ex Div Date	2025-06-16
Last Dividend	TWD 2.12
Payout Frequency	Annual
Payout Ratio	55.17%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-19.11%
1Y total return	9.49%
200-day SMA	52.72
3Y total return	22.28%
50-day SMA	51.64
50-day SMA vs 200-day SMA	50under200
5Y total return	39.53%
All Time High	116.1
All Time High Change	-55.82%
All Time High Date	2012-03-26
All Time Low	34.95
All Time Low Change	46.78%
All Time Low Date	2015-08-25
ATR	0.8
Beta	0.33
Beta1y	0.21
Beta2y	0.45
Ch YTD	-12.31
High	51.4
High52	59.3
High52 Date	2025-12-16
High52ch	-13.49%
Low	50.7
Low52	45.9
Low52 Date	2025-08-11
Low52ch	11.77%
Ma50ch	-0.66%
Price vs 200-day SMA	-2.7%
RSI	51.56
RSI Monthly	46.49
RSI Weekly	42.01
Sharpe ratio	0.62x
Sortino ratio	1.34
Total Return	4.87%
Tr YTD	-12.31
Tr1m	0.2%
Tr1w	3.12%
Tr3m	-8.56%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	TWD 228.5M
Operating Income Growth	35.58
Operating Income Growth Q	23.54
Operating Income Growth3 Y	73.4
Operating Income Growth5 Y	32.98
Operating margin	17.11

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	15,121,950%
Net Borrowing	-12,462,000
Shares Insiders	1.03%
Shares Institutions	0.72%
Shares Out	38,398,140
Shares Qo Q	0.64%
Shares Yo Y	0.22%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	TWD 276.3M
Average Volume	36,252.5x
Bv Per Share	38.1
CAPEX	TWD -3.2M
Ch10y	-41.1
Ch1m	0.2
Ch1w	3.12
Ch1y	4.91
Ch3m	-8.56
Ch3y	10.8
Ch5y	16.59
Ch6m	-5.7
Change	0.98%
Change From Open	0.39
Close	50.8
Days Gap	0.59
Depreciation Amortization	13,455,000
Dollar Volume	1,284,039
Earnings Date	2026-08-03
EBIT	TWD 228.5M
EBITDA	TWD 241.9M
EPS	TWD 3.83
F Score	6
FCF	TWD 276.3M
FCF EV Yield	16.42x
FCF Per Share	TWD 7.2
Financing CF	-98,726,000
Fiscal Year End	December
Founded	2,000
Graham Number	57.29242
Graham Upside	11.68
Income Tax	TWD 50.7M
Investing CF	-128,763,000
Is Primary Listing	1
Last Earnings Date	2026-02-24
Last Report Date	2026-03-31
Last Split Date	2013-08-28
Last Split Type	Forward
Lynch Fair Value	TWD 95.73
Lynch Upside	86.6
Ma150	54.02
Ma150ch	-5.03%
Ma20	50.96
Ma20ch	0.66%
Net CF	52,037,000
Next Earnings Date	2026-08-03
Open	51.1
P FCF Ratio	7.13
P OCF Ratio	7.05
Payment Date	2025-07-11
Position In Range	85.71
Ppne	33,268,000
Price Date	2026-05-08
Price EBITDA	TWD 8.14
Ptbv Ratio	1.67
Relative Volume	0.69x
Revenue	1,335,222,000x
Tax By Revenue	3.8x
Tax Rate	20.7%
Tr6m	-5.7%
Volume	25,030

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

TPEX/8432 dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+5.1%

$2.61 annual per share

Payout ratio

+55.2%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+3.3%

1 consecutive years of growth

Total shareholder yield

+4.9%

Next ex-dividend date: 2025-06-16

Performance

TPEX/8432 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TPEX/8432?

Insider, institutional, and short-interest positioning.

Institutional ownership

+0.7%

Share of float held by funds and institutions

Insider ownership

+1.0%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.2%

Negative means the company is buying back shares.

Technical

TPEX/8432 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

51.6

Neutral momentum band

Price vs 200-day MA

-2.7%

50/200-day relationship not available

Beta (5Y)

0.33

Less volatile than the market

Sharpe ratio

0.62

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TPEX/8432

Hub-level FAQ points readers to the deeper analysis pages.

What is the current tpex/8432 stock rating?

tpex/8432 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full tpex/8432 analysis?

The full report lives at /stocks/tpex/8432/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for tpex/8432?

The latest report frames tpex/8432 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the tpex/8432 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.